Clinical trials: Inflammation; Skin
Abscess
Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage
Cutaneous abscesses (boils) are collections of pus or infection in the skin, and are a frequent reason for emergency department visits.
- Trial name
- NCT01673061
- Testing
- Lidocaine, Vapocoolant
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Albert Einstein Healthcare Network
Lupus Erythematosus, Systemic, Musculoskeletal Pain
Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune, inflammatory disease and musculoskeletal pain is one of the most common symptoms.
- Trial name
- NCT02822989
- Testing
- Vagus nerve stimulation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Northwell Health
Atopic Dermatitis
Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
To evaluate the safety, efficacy (dose response) and pharmacokinetics of 0.3% and 1% OPA-15406 when applied twice daily for 4 weeks in pediatric patients with atopic dermatitis.
- Trial name
- NCT03018691
- Testing
- OPA-15406
- Where
- 4 sites in Japan
- Volunteers
- 73 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis
Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)
The purpose and (primary) objectives of this study are to evaluate the efficacy, safety, and tolerability of TS-022 in adults with atopic dermatitis who have moderate to very severe pruritus (itching), following a 28-day regimen…
- Trial name
- NCT00914186
- Testing
- TS022, Vehicle
- Where
- 15 sites in United States
- Volunteers
- 122 people
- Sponsor
- Taisho Pharmaceutical R&D Inc.
Atopic Dermatitis Eczema
Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis
This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 28 days vs vehicle application on treatment of mild to moderate AD
- Trial name
- NCT03235024
- Testing
- B244, Vehicle
- Where
- 17 sites in United States
- Volunteers
- 122 people
- Sponsor
- AOBiome LLC
Inflammation, Rheumatoid Arthritis
First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetic (the effect of the body on the investigated drug) and signs of clinical efficacy of increasing single…
- Trial name
- NCT00927927
- Testing
- NNC0142-0002
- Where
- Germany
- Volunteers
- 65 people
- Sponsor
- Janssen Research & Development, LLC
Dermatitis, Seborrheic
STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%
Extina (ketoconazole) Foam, 2% was approved for marketing in the United States (US) in June 2007. Extina foam is indicated for topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older.
- Trial name
- NCT00703846
- Testing
- Ketoconazole
- Volunteers
- 498 people
- Sponsor
- Stiefel, a GSK Company